{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:45:24Z","timestamp":1788432324626,"version":"build-2803163510"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.<\/jats:p>","DOI":"10.4103\/ijd.ijd_580_22","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:26:16Z","timestamp":1715739976000},"page":"459-462","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab-Associated Sezary Syndrome"],"prefix":"10.4103","volume":"68","author":[{"given":"Austin","family":"Hamp","sequence":"first","affiliation":[{"name":"From the Arizona College of Osteopathic Medicine, Glendale, Arizona, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Saint Louis University School of Medicine, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Alhatem","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saint Louis University School of Medicine, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pathology, Rutgers New Jersey Medical School, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","article-title":"The role of interleukins 4 and\/or 13 in the pathophysiology and treatment of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1590\/abd1806-4841.20187106","article-title":"Clinical and epidemiological profile of patients with early stage mycosis fungoides","volume":"93","author":"Amorim","year":"2018","journal-title":"An Bras Dermatol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.17001","article-title":"Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome","volume":"35","author":"Steck","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.abd.2020.12.007","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Focus on the current treatment scenario","volume":"96","author":"Sanches","year":"2021","journal-title":"An Bras Dermatol"},{"key":"R7-20240829","first-page":"211","article-title":"Surgical management of mycosis fungoides","volume":"28","author":"Lambert","year":"1997","journal-title":"J Med"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"9717530","DOI":"10.1155\/2016\/9717530","article-title":"S\u00e9zary syndrome and atopic dermatitis: Comparison of immunological aspects and targets","volume":"2016","author":"Saulite","year":"2016","journal-title":"Biomed Res Int"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"AQMycosis 3fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol."}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_580_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:33:48Z","timestamp":1787769228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_580_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_580_22","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}